Discovery of elfamycin-class inhibitors combating carbapenem-resistant Acinetobacter baumannii from the Antarctic-derived Streptomyces sp. A3-7

Key Points

• Elfamycin-class inhibitors showed promising activity against carbapenem-resistant Acinetobacter baumannii.
• Testing highlighted an inhibitory effect in 80% of the strains assessed, indicating significant potential.
• The analysis focused on compounds derived from a cultured Antarctic Streptomyces sp. isolate in lab conditions.
• These findings support the exploration of novel antimicrobial treatments, especially against resistant bacteria.